|
NEUROMUSCULAR BLOCKING EFFECT IS ENHANCED
|
NEUROMUSCULAR BLOCKING EFFECT IS ENHANCED
|
NEUROMUSCULAR BLOCKING EFFECT IS ENHANCED
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
SYMPATHOMIMETICS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CONCOMITANT USE MAY CAUSE SEVERE CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY CAUSE SEVERE CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY CAUSE SEVERE CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY CAUSE SEVERE CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY CAUSE SEVERE CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY CAUSE SEVERE CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY CAUSE SEVERE CARDIAC ARRHYTHMIAS
|
SYMPATHOMIMETICS MAY ANTAGONISE THE HYPOTENSIVE EFFECTS OF METHYLDOPA
|
OXYTOCIN MAY POTENTIATE THE PRESSOR EFFECT OF SYMPATHOMIMETIC-VASOCONSTRICTOR AGENTS LIKE ADRENALINE, ISOPRENALINE ETC
|
SYMPATHOMIMETICS HYPERTENSIVE & VASOCONSTRICTOR EFFECT IS POTENTIATED BY THE DRUG
|
SYMPATHOMIMETICS HYPERTENSIVE & VASOCONSTRICTOR EFFECT IS POTENTIATED BY THE DRUG
|
SYMPATHOMIMETICS HYPERTENSIVE & VASOCONSTRICTOR EFFECT IS POTENTIATED BY THE DRUG
|
SYMPATHOMIMETICS HYPERTENSIVE & VASOCONSTRICTOR EFFECT IS POTENTIATED BY THE DRUG
|
SYMPATHOMIMETICS HYPERTENSIVE & VASOCONSTRICTOR EFFECT IS POTENTIATED BY THE DRUG
|
SYMPATHOMIMETICS HYPERTENSIVE & VASOCONSTRICTOR EFFECT IS POTENTIATED BY THE DRUG
|
SYMPATHOMIMETICS HYPERTENSIVE & VASOCONSTRICTOR EFFECT IS POTENTIATED BY THE DRUG
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
BETABLOCKERS MAY INHIBIT THE EFFECT OF BETASTIMULANTS LIKE BAMBUTEROL, XANTHINE DERIVATIVES & VICE VERSA
|
BETABLOCKERS MAY INHIBIT THE EFFECT OF BETASTIMULANTS LIKE BAMBUTEROL, XANTHINE DERIVATIVES & VICE VERSA
|
BETABLOCKERS MAY INHIBIT THE EFFECT OF BETASTIMULANTS LIKE BAMBUTEROL, XANTHINE DERIVATIVES & VICE VERSA
|
BETABLOCKERS MAY INHIBIT THE EFFECT OF BETASTIMULANTS LIKE BAMBUTEROL, XANTHINE DERIVATIVES & VICE VERSA
|
BETABLOCKERS MAY INHIBIT THE EFFECT OF BETASTIMULANTS LIKE BAMBUTEROL, XANTHINE DERIVATIVES & VICE VERSA
|
BETABLOCKERS MAY INHIBIT THE EFFECT OF BETASTIMULANTS LIKE BAMBUTEROL, XANTHINE DERIVATIVES & VICE VERSA
|
BETABLOCKERS MAY INHIBIT THE EFFECT OF BETASTIMULANTS LIKE BAMBUTEROL, XANTHINE DERIVATIVES & VICE VERSA
|
BETABLOCKERS MAY INHIBIT THE EFFECT OF BETASTIMULANTS LIKE BAMBUTEROL, XANTHINE DERIVATIVES & VICE VERSA
|
BETABLOCKERS MAY INHIBIT THE EFFECT OF BETASTIMULANTS LIKE BAMBUTEROL, XANTHINE DERIVATIVES & VICE VERSA
|
BETABLOCKERS MAY INHIBIT THE EFFECT OF BETASTIMULANTS LIKE BAMBUTEROL, XANTHINE DERIVATIVES & VICE VERSA
|
BETABLOCKERS MAY INHIBIT THE EFFECT OF BETASTIMULANTS LIKE BAMBUTEROL, XANTHINE DERIVATIVES & VICE VERSA
|
BETABLOCKERS MAY INHIBIT THE EFFECT OF BETASTIMULANTS LIKE BAMBUTEROL, XANTHINE DERIVATIVES & VICE VERSA
|
BETABLOCKERS MAY INHIBIT THE EFFECT OF BETASTIMULANTS LIKE BAMBUTEROL, XANTHINE DERIVATIVES & VICE VERSA
|
BETABLOCKERS MAY INHIBIT THE EFFECT OF BETASTIMULANTS LIKE BAMBUTEROL, XANTHINE DERIVATIVES & VICE VERSA
|
BETABLOCKERS MAY INHIBIT THE EFFECT OF BETASTIMULANTS LIKE BAMBUTEROL, XANTHINE DERIVATIVES & VICE VERSA
|
BETABLOCKERS MAY INHIBIT THE EFFECT OF BETASTIMULANTS LIKE BAMBUTEROL, XANTHINE DERIVATIVES & VICE VERSA
|
BETABLOCKERS MAY INHIBIT THE EFFECT OF BETASTIMULANTS LIKE BAMBUTEROL, XANTHINE DERIVATIVES & VICE VERSA
|
BETABLOCKERS MAY INHIBIT THE EFFECT OF BETASTIMULANTS LIKE BAMBUTEROL, XANTHINE DERIVATIVES & VICE VERSA
|
BETABLOCKERS MAY INHIBIT THE EFFECT OF BETASTIMULANTS LIKE BAMBUTEROL, XANTHINE DERIVATIVES & VICE VERSA
|
BETABLOCKERS MAY INHIBIT THE EFFECT OF BETASTIMULANTS LIKE BAMBUTEROL, XANTHINE DERIVATIVES & VICE VERSA
|
INCREASED RISK OF HYPOKALEMIA
|
INCREASED RISK OF HYPOKALEMIA
|
INCREASED RISK OF HYPOKALEMIA
|
INCREASED RISK OF HYPOKALEMIA
|
INCREASED RISK OF HYPOKALEMIA
|
INCREASED RISK OF HYPOKALEMIA
|
INCREASED RISK OF HYPOKALEMIA
|
INCREASED RISK OF HYPOKALEMIA
|
INCREASED RISK OF HYPOKALEMIA
|
INCREASED RISK OF HYPOKALEMIA
|
INCREASED RISK OF HYPOKALEMIA
|
INCREASED RISK OF HYPOKALEMIA
|
ALKALINIZATION OF URINE PROLONGS THE HALF LIFE OF SYMPATHOMIMETICS AND SO ACTION
|
ALKALINIZATION OF URINE PROLONGS THE HALF LIFE OF SYMPATHOMIMETICS AND SO ACTION
|
ALKALINIZATION OF URINE PROLONGS THE HALF LIFE OF SYMPATHOMIMETICS AND SO ACTION
|
ALKALINIZATION OF URINE PROLONGS THE HALF LIFE OF SYMPATHOMIMETICS AND SO ACTION
|
ALKALINIZATION OF URINE PROLONGS THE HALF LIFE OF SYMPATHOMIMETICS AND SO ACTION
|
ALKALINIZATION OF URINE PROLONGS THE HALF LIFE OF SYMPATHOMIMETICS AND SO ACTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|